Is Entrada Therapeutics Stock a Good Investment?
Entrada Therapeutics Investment Advice | TRDA |
- Examine Entrada Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Entrada Therapeutics' leadership team and their track record. Good management can help Entrada Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Entrada Therapeutics' business and its evolving consumer preferences.
- Compare Entrada Therapeutics' performance and market position to its competitors. Analyze how Entrada Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Entrada Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Entrada Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Entrada Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Entrada Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | OK | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Entrada Therapeutics Stock
Researching Entrada Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Entrada Therapeutics had not issued any dividends in recent years.
To determine if Entrada Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Entrada Therapeutics' research are outlined below:
| Entrada Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 129.01 M. Net Loss for the year was (6.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entrada Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Entrada Therapeutics Is a Great Choice for Trend Investors, Heres Why |
Entrada Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Entrada Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Entrada Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Entrada Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Entrada Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Entrada Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-08 | 2023-06-30 | -0.69 | -0.78 | -0.09 | 13 | ||
2024-03-13 | 2023-12-31 | -0.17 | -0.29 | -0.12 | 70 | ||
2024-11-05 | 2024-09-30 | -0.625 | -0.35 | 0.275 | 44 | ||
2022-03-15 | 2021-12-31 | -1.28 | -0.89 | 0.39 | 30 | ||
2023-05-10 | 2023-03-31 | 0.97 | -0.21 | -1.18 | 121 | ||
2024-05-07 | 2024-03-31 | -0.59 | 0.68 | 1.27 | 215 | ||
2024-08-06 | 2024-06-30 | 0.14 | 1.5499 | 1.4099 | 1007 | ||
2023-11-07 | 2023-09-30 | -0.74 | 1.02 | 1.76 | 237 |
Know Entrada Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Entrada Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Entrada Therapeutics backward and forwards among themselves. Entrada Therapeutics' institutional investor refers to the entity that pools money to purchase Entrada Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 576.5 K | State Street Corp | 2024-06-30 | 445.2 K | Northern Trust Corp | 2024-09-30 | 247.7 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 201.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 186 K | Millennium Management Llc | 2024-06-30 | 147.3 K | Bank Of New York Mellon Corp | 2024-06-30 | 125.4 K | Nuveen Asset Management, Llc | 2024-06-30 | 122.9 K | Moore Capital Management, Lp | 2024-06-30 | 105 K | Baker Bros Advisors Lp | 2024-09-30 | 4.9 M | Mpm Asset Management, Llc | 2024-09-30 | 4.4 M |
Entrada Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 712.48 M.Market Cap |
|
Entrada Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.03) | (0.03) |
Determining Entrada Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Entrada Therapeutics is a good buy. For example, gross profit margin measures Entrada Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Entrada Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Entrada Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Entrada Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Entrada Therapeutics' management manipulating its earnings.
Evaluate Entrada Therapeutics' management efficiency
Entrada Therapeutics has return on total asset (ROA) of 0.0695 % which means that it generated a profit of $0.0695 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1642 %, meaning that it created $0.1642 on every $100 dollars invested by stockholders. Entrada Therapeutics' management efficiency ratios could be used to measure how well Entrada Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.01. In addition to that, Return On Capital Employed is expected to decline to -0.01. At present, Entrada Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 7.1 M, whereas Total Assets are forecasted to decline to about 239.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.33 | 7.70 | |
| Tangible Book Value Per Share | 7.33 | 7.70 | |
| Enterprise Value Over EBITDA | -1.6 K | -1.5 K | |
| Price Book Value Ratio | 2.06 | 2.16 | |
| Enterprise Value Multiple | -1.6 K | -1.5 K | |
| Price Fair Value | 2.06 | 2.16 | |
| Enterprise Value | 499.4 M | 569.3 M |
Management at Entrada Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta (0.27) |
Basic technical analysis of Entrada Stock
As of the 26th of November, Entrada Therapeutics shows the Mean Deviation of 2.37, downside deviation of 3.11, and Coefficient Of Variation of 1226.1. In respect to fundamental indicators, the technical analysis model provides you with a way to check existing technical drivers of Entrada Therapeutics, as well as the relationship between them.Entrada Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entrada Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entrada Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Entrada Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Entrada Therapeutics' Outstanding Corporate Bonds
Entrada Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Entrada Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Entrada bonds can be classified according to their maturity, which is the date when Entrada Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Entrada Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Entrada Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.07 | |||
| Market Risk Adjusted Performance | 0.1227 | |||
| Mean Deviation | 2.37 | |||
| Semi Deviation | 2.88 | |||
| Downside Deviation | 3.11 | |||
| Coefficient Of Variation | 1226.1 | |||
| Standard Deviation | 3.3 | |||
| Variance | 10.88 | |||
| Information Ratio | 0.0426 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | 0.0451 | |||
| Treynor Ratio | 0.1127 | |||
| Maximum Drawdown | 18.81 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 6.14 | |||
| Downside Variance | 9.7 | |||
| Semi Variance | 8.31 | |||
| Expected Short fall | (2.71) | |||
| Skewness | (0.09) | |||
| Kurtosis | 2.45 |
| Risk Adjusted Performance | 0.07 | |||
| Market Risk Adjusted Performance | 0.1227 | |||
| Mean Deviation | 2.37 | |||
| Semi Deviation | 2.88 | |||
| Downside Deviation | 3.11 | |||
| Coefficient Of Variation | 1226.1 | |||
| Standard Deviation | 3.3 | |||
| Variance | 10.88 | |||
| Information Ratio | 0.0426 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | 0.0451 | |||
| Treynor Ratio | 0.1127 | |||
| Maximum Drawdown | 18.81 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 6.14 | |||
| Downside Variance | 9.7 | |||
| Semi Variance | 8.31 | |||
| Expected Short fall | (2.71) | |||
| Skewness | (0.09) | |||
| Kurtosis | 2.45 |
Consider Entrada Therapeutics' intraday indicators
Entrada Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Entrada Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 3603.71 | |||
| Daily Balance Of Power | 0.4521 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 19.17 | |||
| Day Typical Price | 19.24 | |||
| Price Action Indicator | 0.36 | |||
| Period Momentum Indicator | 0.33 |
Entrada Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Entrada Stock media impact
Far too much social signal, news, headlines, and media speculation about Entrada Therapeutics that are available to investors today. That information is available publicly through Entrada media outlets and privately through word of mouth or via Entrada internal channels. However, regardless of the origin, that massive amount of Entrada data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Entrada Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Entrada Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Entrada Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Entrada Therapeutics alpha.
Entrada Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Entrada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Entrada Therapeutics Corporate Management
| Kory CPA | CFO Treasurer | Profile | |
| Kerry MS | Senior People | Profile | |
| Jared JD | General Counsel | Profile | |
| Nathan Dowden | Chief Officer | Profile | |
| Karla MacDonald | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Entrada Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.